LIDo banner

Contact us

Don't hesitate to contact the programme if you have any questions about applying or if you are interested in exploring ways you can engage with LIDo and our students

Bisbiguanide analogues as probes for assessing membrane barrier function in multidrug resistant Gram-negative bacteria.
Closing date
research image
Supervisors
Dr Miraz Rahman, k.miraz.rahman@kcl.ac.uk, Research activities in Rahman group are focused on the application of advanced computational chemistry, synthetic medicinal chemistry and chemical biology techniques, King’s College London
Project Details

The discovery of new antibiotics effective against Gram-negative bacteria is a major challenge due to the permeability barrier of the two-membrane cell envelope of Gram-negative bacteria and limited chemical diversity of compound libraries to probe this barrier. The expansion of the chemical space of antibacterial tool compounds and identification of compounds that can penetrate the Gram-negative membrane barrier is urgent to understand the chemical features of compounds that are able to overcome the Gram-negative membrane barrier. The industrial applicants have previously been involved in screening of the Prestwick Chemical Library, commissioned by ANTRUK, and identified a small limited number of compounds which either showed direct antimicrobial effects against multidrug resistant Gram-negative pathogens or which were able to synergise with specific antibiotics  to potentiate their activity against resistant isolates (Hind et al 2019). Two related compounds, chlorhexidine and alexidine, showed high levels of potentiation against all of the strains tested. These bisbiguanides are well characterised antiseptic agents used in a wide range of clinical settings, but the scaffold has not been rigorously explored to understand whether derivatives have separable membrane permeabilising activity and antibacterial properties.

Bisbiguanides offer an excellent chemical scaffold for probe development due to their ability to interact with Gram-negative membranes. We will use these probes to improve the understanding of the molecular basis for low-permeability barriers of the problematic Gram-negative pathogens and define the physicochemical properties that enable uptake of various compounds into bacterial cells using probes synthesied as part of this PhD project. Coupled with other methods for studying membrane perturbation, including whole genome sequencing of ESKAPE mutants generated by serial passage (where resistance emerges), and strain libraries with known modifications in membrane structure/function, will provide a powerful new basis for understanding uptake, and the ability of compounds to penetrate or disrupt bacterial membranes.

The study will also look at the properties of membrane active compounds like bisbiguanides which restrict their potential use for systemic therapy; specifically their eukaryotic cell toxicity. The project will extend the studies exploring interaction of biguanides with the bacterial membrane to include an assessment of their activity in mammalian membranes, to further extend our understanding of their structure activity relationship.

In this interdisciplinary project the student will work at the interface of computational chemistry, medicinal chemistry and microbiology.

Year 1: The project will involve initial training and utilisation of molecular modelling and computational techniques to study the interaction of bisbiguanides with Gram-negative membranes and design probes for synthesis. To serve as probes and for SAR determination, fluorophores with different sensitivities to the polar environment will be added onto existing scaffolds.

Year 2-3: The student will use a range of molecular biology techniques and a new bacterial membrane impedance assay to explore the interaction and partitioning of probes with bacterial membranes from a range of species and with known resistance modifications. This will allow us to develop a new understanding of the Gram-negative membrane barrier and chemical features to overcome them which can be applied to enhance activity of known antibacterial scaffolds with poor penetration.

Year 3-4: Optimisation of probes to separate the bacterial and mammalian membrane disrupting activity. These modifications, based on our improved understanding of mechanism of binding and disruption, may allow the development of more refined membrane probes or candidate antimicrobial agents for further development.

References
  1. Picconi, P., Hind, C., Nahar, K.S., Jamshidi, S., Di Maggio, L., Saeed, N., Evans, B., Solomons, J., Wand, M.E., Sutton, J.M. and Rahman, K.M., (2020). New broad-spectrum antibiotics containing a pyrrolobenzodiazepine ring with activity against multidrug resistant Gram-negative bacteria. Journal of Medicinal Chemistry. 63, 13, 6941–6958
  2. Wand, M.E., Taylor, H.V., Auer, J.L., Bock, L.J., Hind, C.K., Jamshidi, S., Rahman, K.M. and Sutton, J.M., (2019). Evaluating the level of nitroreductase activity in clinical isolates of Klebsiella pneumoniae to support strategies for nitro drug and prodrug development. International journal of antimicrobial agents 54, 538-546.
  3. Hind CK, Dowson CG, Sutton JM, Jackson T, Clifford M, Garner RC, Czaplewski L. Evaluation of a Library of FDA-Approved Drugs for Their Ability to Potentiate Antibiotics against Multidrug-Resistant Gram-Negative Pathogens Antimicrob Agents Chemother. (2019) 63(8): e00769-19. 
  4. Wand, M. E., Jamshidi, S., Bock, L. J., Rahman, K. M., and Sutton, J. M. (2019) SmvA is an important efflux pump for cationic biocides in Klebsiella pneumoniae and other Enterobacteriaceae, Scientific reports 9, 1344.
  5. Andriollo, P., Hind, C. K., Picconi, P., Nahar, K. S., Jamshidi, S., Varsha, A., Clifford, M., Sutton, J. M., and Rahman, K. M. (2018) C8-Linked Pyrrolobenzodiazepine Monomers with Inverted Building Blocks Show Selective Activity against Multidrug Resistant Gram-Positive Bacteria, ACS Infectious Diseases 4, 158-174.
  6. Picconi, P., Hind, C., Janashidi, S., Nahar, K., Clifford, M., Wand, M. E., Sutton, J. M., and Rahman, K. M. (2017) Triaryl Benzimidazoles as a New Class of Antibacterial Agents against Resistant Pathogenic Microorganisms, Journal of Medicinal Chemistry 60, 6045-6059

If given the choice between LIDo and any other doctoral training program, I choose LIDo every time

Alexandra Richardson

The LIDo Programme has revolutionised my view of modern biomedical research. It pushed me to step outside of my comfort zone and to explore research areas which I never considered to enjoy beforehand. My PhD project made me look at large biological datasets in a computational way and I do not regret a single thing I learned on my deep learning journey

Kristina Ulicna

LIDo cultivates a close relationship with the wider life sciences and technology industries to advise upon and guide our outreach activities and student awareness of tracks outside of academia, including entrepreneurial opportunities.

Dr. Renos Savva

LIDo was perfect for me, because of its interdisciplinarity and the opportunities it offered!

Dr. Pedro Almada

LIDo helped me discover a new career path and learn new skills, that I never thought I would be interested in. LIDo has encouraged me to take more risks and experience new sides of research.

Sarah Aliko

LIDo provides a fantastic training environment for cross-disciplinary research

Dr. Viji Draviam

LIDo is like a huge extended family, everyone is willing to help each other out and offer advice which is particularly important when you’re faced with challenges in your research!

Justine Pearce

The best decision I ever made!

Isabel Fletcher

I never thought debating would be helpful to a researcher, but after a LIDo provided debate workshop I felt much more comfortable answering questions at a recent conference!

Freddy Sarathchandra

LIDo gave me the confidence to pursue a PhD in a field I would never have considered before. The sense of community the programme has to offer is second to none, fostering solid friendships and providing a platform to encourage one another along our journeys, both in and out of the lab.

Dr. Michael Coghlan

From LIDo to Leaders in modern biomedicine

Professor Michelangelo Campanella